Compare Biocon Ltd with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs CADILA HEALTHCARE - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON CADILA HEALTHCARE BIOCON /
CADILA HEALTHCARE
 
P/E (TTM) x 28.1 29.6 94.7% View Chart
P/BV x 3.2 3.5 89.5% View Chart
Dividend Yield % 0.3 1.0 31.9%  

Financials

 BIOCON    CADILA HEALTHCARE
EQUITY SHARE DATA
    BIOCON
Mar-19
CADILA HEALTHCARE
Mar-19
BIOCON /
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs707432 163.6%   
Low Rs554306 180.7%   
Sales per share (Unadj.) Rs91.9128.6 71.5%  
Earnings per share (Unadj.) Rs16.718.5 90.1%  
Cash flow per share (Unadj.) Rs24.224.4 99.1%  
Dividends per share (Unadj.) Rs1.003.50 28.6%  
Dividend yield (eoy) %0.20.9 16.7%  
Book value per share (Unadj.) Rs101.6101.5 100.2%  
Shares outstanding (eoy) m600.001,023.74 58.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.92.9 238.9%   
Avg P/E ratio x37.719.9 189.5%  
P/CF ratio (eoy) x26.115.1 172.3%  
Price / Book Value ratio x6.23.6 170.4%  
Dividend payout %6.018.9 31.7%   
Avg Mkt Cap Rs m378,330378,170 100.0%   
No. of employees `0006.112.4 49.3%   
Total wages/salary Rs m11,65321,241 54.9%   
Avg. sales/employee Rs Th8,994.310,585.0 85.0%   
Avg. wages/employee Rs Th1,900.71,707.8 111.3%   
Avg. net profit/employee Rs Th1,635.31,526.5 107.1%   
INCOME DATA
Net Sales Rs m55,144131,656 41.9%  
Other income Rs m1,4442,011 71.8%   
Total revenues Rs m56,588133,667 42.3%   
Gross profit Rs m15,88329,731 53.4%  
Depreciation Rs m4,4785,986 74.8%   
Interest Rs m7091,935 36.6%   
Profit before tax Rs m12,14023,821 51.0%   
Minority Interest Rs m9469 1.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1235,303 40.0%   
Profit after tax Rs m10,02618,987 52.8%  
Gross profit margin %28.822.6 127.5%  
Effective tax rate %17.522.3 78.6%   
Net profit margin %18.214.4 126.1%  
BALANCE SHEET DATA
Current assets Rs m48,22884,981 56.8%   
Current liabilities Rs m30,37673,425 41.4%   
Net working cap to sales %32.48.8 368.8%  
Current ratio x1.61.2 137.2%  
Inventory Days Days6875 91.6%  
Debtors Days Days86110 78.1%  
Net fixed assets Rs m64,130133,493 48.0%   
Share capital Rs m3,0001,024 293.0%   
"Free" reserves Rs m57,980102,839 56.4%   
Net worth Rs m60,980103,863 58.7%   
Long term debt Rs m15,76639,497 39.9%   
Total assets Rs m121,924234,831 51.9%  
Interest coverage x18.113.3 136.2%   
Debt to equity ratio x0.30.4 68.0%  
Sales to assets ratio x0.50.6 80.7%   
Return on assets %8.88.9 98.8%  
Return on equity %16.418.3 89.9%  
Return on capital %16.818.3 91.6%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50648,404 32.0%   
Fx outflow Rs m10,39911,593 89.7%   
Net fx Rs m5,10736,811 13.9%   
CASH FLOW
From Operations Rs m11,54628,823 40.1%  
From Investments Rs m-7,138-57,387 12.4%  
From Financial Activity Rs m-2,41718,846 -12.8%  
Net Cashflow Rs m2,103-7,105 -29.6%  

Share Holding

Indian Promoters % 40.4 74.8 54.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.3 101.2%  
FIIs % 10.7 5.9 181.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 11.0 180.9%  
Shareholders   109,995 44,069 249.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   PANACEA BIOTECH  AJANTA PHARMA  ALEMBIC LTD  ALKEM LABORATORIES  ELDER PHARMA  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Turn Volatile; Telecom & IT Stocks Under Pressure(12:30 pm)

Share markets in India are presently trading on a volatile note. While Indian share markets opened on a negative note today.

Related Views on News

IPCA LABS at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Apr 8, 2020 | Updated on Apr 8, 2020

IPCA LABS share price has hit a 52-week high. It is presently trading at Rs 1,821. BSE 500 Index is up by 1.1% at 11,802. Within the BSE 500, IPCA LABS (up 6.0%) and CUMMINS INDIA (up 14.6%) are among the top gainers, while top losers are AMBER ENTERPRISES INDIA LTD and FUTURE LIFESTYLE.

WOCKHARDT Surges by 6%; BSE HEALTHCARE Index Up 3.6% (Market Updates)

Apr 8, 2020 | Updated on Apr 8, 2020

WOCKHARDT share price has surged by 6% and its current market price is Rs 214. The BSE HEALTHCARE is up by 3.6%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 5.8%) and IPCA LABS (up 18.8%). The top losers are FORTIS HEALTHCARE (down 0.4%) and GSK PHARMA (down 0.7%).

IPCA LABS Surges by 13%; BSE HEALTHCARE Index Up 3.1% (Market Updates)

Apr 8, 2020 | Updated on Apr 8, 2020

IPCA LABS share price has surged by 13% and its current market price is Rs 1,717. The BSE HEALTHCARE is up by 3.1%. The top gainers in the BSE HEALTHCARE Index are IPCA LABS (up 12.6%) and CADILA HEALTHCARE (up 10.0%). The top losers are GSK PHARMA (down 0.3%) and FORTIS HEALTHCARE (down 0.6%).

ALEMBIC PHARMA at 52 Week High; BSE 500 Index Up 3.0% (Market Updates)

Apr 8, 2020 | Updated on Apr 8, 2020

ALEMBIC PHARMA share price has hit a 52-week high. It is presently trading at Rs 702. BSE 500 Index is up by 2.7% at 11,653. Within the BSE 500, ALEMBIC PHARMA (up 10.1%) and JINDAL STEEL & POWER (up 15.0%) are among the top gainers, while top losers are FUTURE LIFESTYLE and FUTURE CONSUMER.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Apr 8, 2020 02:21 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS